Japanese participant data from three gantenerumab trials in early Alzheimer's disease.

ABSTRACT:

Introduction

Gantenerumab was investigated in Japanese participants with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD in two global phase 3 trials (GRADUATE I/II), and a phase 2 trial in Japan (JP40959).

Methods

Of 1965 participants randomized in GRADUATE I/II (global-GRADUATE), 132 participants were enrolled from Japan (Japanese-GRADUATE) and 67 Japanese participants were randomized 2:1:1 to high-, low-dose gantenerumab, and placebo in JP40959.

Results

Slowing of cognitive and functional decline, and amyloid reduction in gantenerumab group compared to placebo group were greater in Japanese-GRADUATE than in the global-GRADUATE and JP40959. Plasma gantenerumab concentrations in the Japanese-GRADUATE were slightly higher than in the global-GRADUA

SUBMITTER: Asada T 

PROVIDER: S-EPMC12040720 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature